Conakry

ZMapp TM is the result of a collaboration between Mapp Biopharmaceutical Inc. and LeafBio (San Diego, CA), Defyrus Inc. (Toronto, Canada), the U.S. government and the Public Health Agency of Canada (PHAC).

ZMapp TM is composed of three “humanized” monoclonal antibodies manufactured in plants, specifically Nicotiana.  It is an optimized cocktail combining the best components of MB-­‐003 (Mapp) and ZMAb (Defyrus/PHAC).

ZMapp TM was first identified as a drug candidate in January 2014 and has not yet been evaluated for safety in humans.  As such very little of the drug is currently available.  

Any decision to use an experimental drug in a patient would be a decision made by the treating physician under the regulatory guidelines of the FDA.

Mapp and its partners are cooperating with appropriate government agencies to increase production as quickly as possible.

CLICK HERE - ZMapp - Information Sheet (1 page .PDF file)

http://www.mappbio.com/

cnn.com - by By Jacque Wilson and Danielle Dellorto - August 5, 2014

(CNN) -- Two American missionary workers infected with the deadly Ebola virus were given an experimental drug that seems to have saved their lives.

Dr. Kent Brantly was given the medication, ZMapp, shortly after telling his doctors he thought he would die, according to a source familiar with his case. Within an hour, doctors say his symptoms -- labored breathing and a widespread rash -- dramatically improved. Nancy Writebol, another missionary working with Samaritan's Purse, received two doses of the medication and has also shown significant improvement, sources say.

As there is no proven treatment and no vaccine for Ebola, this experimental drug is raising lots of questions.

(READ COMPLETE ARTICLE)